These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22032759)

  • 1. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
    Gallagher JC; Strzinek RA; Cheng RF; Ausmanas MK; Astl D; Seljan P
    J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d.
    Khan A; Musgnung J; Ramey T; Messig M; Buckley G; Ninan PT
    J Clin Psychopharmacol; 2014 Jun; 34(3):365-8. PubMed ID: 24717247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
    Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
    Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
    Cheng RJ; Dupont C; Archer DF; Bao W; Racketa J; Constantine G; Pickar JH
    Climacteric; 2013 Feb; 16(1):17-27. PubMed ID: 22646219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
    Montgomery SA; Fava M; Padmanabhan SK; Guico-Pabia CJ; Tourian KA
    Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.
    Ninan PT; Musgnung J; Messig M; Buckley G; Guico-Pabia CJ; Ramey TS
    Prim Care Companion CNS Disord; 2015; 17(1):. PubMed ID: 26137358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
    Tourian K; Wang Y; Ii Y
    Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
    Archer DF; Pinkerton JV; Guico-Pabia CJ; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):47-56. PubMed ID: 23266840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.
    Berhan Y; Berhan A
    Ethiop J Health Sci; 2014 Jul; 24(3):209-18. PubMed ID: 25183927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying meaningful differences in vasomotor symptoms among menopausal women.
    Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
    Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
    Sun Z; Hao Y; Zhang M
    Gynecol Obstet Invest; 2013; 75(4):255-62. PubMed ID: 23548358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.